Form | white to yellowish crystalline granules or powder |
MF | C5H10O5 |
MW | 150.13 |
Melting point | 87 °C |
Boiling point | 191.65°C (rough estimate) |
Density | 1.1897 (rough estimate) |
Refractive index | -21 ° (C=1, H2O) |
Pka | 12.46±0.20(Predicted) |
Storage temp. | 2-8°C |
Item | Index |
Assay,w% | 97.0~103.0 |
melting point/℃ | 80.0~90.0 |
Specific Rotation(20 ℃) | -21.0°~-19.0° |
loss on drying,w/% | ≤2.0 |
Residue on Ignition,w/% | ≤0.2 |
transmittance/% | ≥95.0 |
Lead(Pb)/(mg/kg) | ≤0.1 |
Arsenic(As)/(mg/kg) | ≤1.0 |
Total Plate count /(CFU/g) | ≤100 |
Mould、Yeast/(CFU/g) | ≤100 |
Coliforms/(CFU/g) | ≤10 |
Salmonella /25g | Negative |
D-ribose, as a pharmaceutical intermediate, has been widely used in the synthesis of riboflavin (VB2), pyran ribose and anti-virus, anti-tumor nucleoside. In health care, D-ribose has been used to treat myocardial ischemia, diabetes and muscle pain (caused by exercise); in food industry, D-ribose, as a natural food sweetener, has been widespread used in Japan and other developed countries.